GERN Stock Forecast: Geron Corp. Price Predictions for 2026-2027
The median 12-month analyst price target for Geron Corp. is $3.25. Ticker Nerd's systematic factor model, run across ~4,300 US stocks, ranks it 71 of 100 as at 21 Nov 2026 — in the upper half.
One number for the whole business
Consensus tells you what everyone already believes. The model scores Geron Corp. on its factor families — the same systematic rank behind the Ticker Nerd portfolio.
Percentile across ~4,300 US stocks on Ticker Nerd’s systematic factor model. Higher is better. How the model is built and tested
Value (93): The shares cost little relative to the profits and assets behind them — which can mean the market is too gloomy, or that the business really is in trouble.
Accruals (24): A large share of reported profit has not shown up as cash, or the balance sheet is expanding quickly — both tend to unwind.
Built and run by Aslam Ghouse, an ex-Goldman Sachs systematic trader with 15+ years in markets.
GERN stock forecast 2026-2027: analyst price targets & predictions
The bullish and bearish analyst opinions on GERN, reported as data — targets and ratings, the market's view beside the model's.
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Data provided by Twelve Data
Of the 20 most recent actions, 0 moved their price target up and 3 moved it down.
| Date | Firm | Action | Rating | Target |
|---|---|---|---|---|
| 29 Oct 2026 | Wedbush | Maintains | Outperform | $6.00 → $5.00 |
| 28 Oct 2026 | Needham | Maintains | Buy | $4.00 → $2.50 |
| 5 Nov 2025 | Needham | Maintains | Buy | $5.00 → $4.00 |
| 10 July 2025 | Goldman Sachs | Reinstates | Sell | $1.00 |
| 8 May 2025 | Scotiabank | Downgrade | Sector Perform | — |
| 12 Mar 2025 | HC Wainwright & Co. | Reiterates | Neutral | — |
| 12 Mar 2025 | Needham | Reiterates | Buy | — |
| 27 Feb 2025 | Barclays | Maintains | Overweight | — |
| 27 Feb 2025 | Needham | Maintains | Buy | — |
| 27 Feb 2025 | Scotiabank | Maintains | Sector Outperform | — |
| 27 Feb 2025 | Stifel | Maintains | Buy | — |
| 26 Feb 2025 | HC Wainwright & Co. | Downgrade | Neutral | — |
| 18 Feb 2025 | B. Riley Securities | Maintains | Buy | — |
| 13 Jan 2025 | Needham | Maintains | Buy | — |
| 13 Dec 2024 | Needham | Reiterates | Buy | — |
| 10 Dec 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 6 Nov 2024 | HC Wainwright & Co. | Reiterates | Buy | — |
| 5 Nov 2024 | HC Wainwright & Co. | Initiates | Buy | — |
| 16 Oct 2024 | Scotiabank | Initiates | Sector Outperform | — |
| 9 Sept 2024 | Leerink Partners | Initiates | Outperform | — |
Price targets and ratings are third-party analyst estimates, reported here as data. They are not Ticker Nerd forecasts, and they are frequently wrong.
Wall Street targets run 12 to 18 months out. No analyst publishes a 2030 price target for GERN.
This page is one stock. Monday covers all of them.
GERN appears in the Radar on the weeks it earns a place.
- Market Radar, every Monday: the week's biggest rank moves across ~4,300 US stocks, and the reason for each.
- The AI build-out map, free: every AI company we track on one page, with the model's Top picks in all four parts.
AI cloud capacity
MSFTAMZNGOOGLORCL
AI chips
NVDAAVGOAMDMU
AI networking and servers
ANETDELLLITECRDO
Data centre power
VRTCEGGEVVST
GERN vs the S&P 500
Both lines are total return — dividends reinvested — so the comparison is honest on both sides.
Over the twelve months to 20 Nov 2026, Geron Corp. returned −20.8% against +6.9% for the S&P 500, dividends included.
Download this chart as an image — free to reuse; link this page as the source.
Data provided by Twelve Data
GERN analyst estimate revisions
Not the forecast itself — the direction analysts are revising it. Revision direction is one of the model's factor families.
Financials
A margin means little on its own. Each bar marks where the figure sits across the whole US universe we score.
- Trailing P/E
- —
- Price / sales
- 2.6×
- Price / book
- 2.5×
- EV / EBITDA
- —
Cheaper than 40% of US stocks
Cheaper than 35% of US stocks
- Revenue growth (YoY)
- —
- Earnings growth (YoY)
- —
- Gross margin
- 83.9%
- Operating margin
- −7.2%
- Net margin
- —
Higher than 93% of US stocks
Higher than 28% of US stocks
- Return on equity
- −20.1%
- Return on assets
- −1.8%
- Dividend yield
- —
Higher than 32% of US stocks
Higher than 38% of US stocks
Bars mark the percentile across the ~4,300 US stocks Ticker Nerd covers, among those reporting the figure.
Key statistics
The headline figures, each with its date. Every row carries its own link — cite it straight from here.
Geron Corp. has a market value of $586.3M and an enterprise value of $422.9M.
Revenue in the twelve months to 30 June 2026: $204.6M. The latest quarter grew 17.2% year on year.
Net income over the same four quarters: −$67.6M, a −33.1% net margin.
Diluted earnings per share, trailing twelve months: −$0.11.
Free cash flow in the twelve months to 30 June 2026: −$114.8M.
forward P/E: 9.9× — the forward figure prices analyst consensus estimates, not reported earnings.
Geron Corp. employs 258 people — $793K of revenue per employee.
Data provided by Twelve Data
GERN and its peers
The nearest names by industry and size, scored by the same model — like for like.
Take a look at GERN’s peer groups, ranked by the model: healthcare stocks · biotech stocks.
Look up any of the roughly 4,300 stocks we score.
The rank is the raw material. Whether the rules would actually own Geron Corp. — and when they’d sell — is the membership. See the Ticker Nerd 20 →
Questions about GERN
What is the GERN stock price forecast for 2026-2027?
The median 12-month analyst price target for Geron Corp. is $3.25, with estimates ranging from $2.5 to $5. These are third-party analyst estimates, not Ticker Nerd forecasts, and they are frequently wrong.
Is GERN stock a buy right now?
Of the 5 analysts covering Geron Corp., 4 rate it a Buy, 1 a Hold and 0 a Sell. Ticker Nerd's systematic factor model ranks Geron Corp. 71 out of 100 across roughly 4,300 US stocks as at 21 Nov 2026. None of this is personal advice — it does not consider your circumstances.
How does Ticker Nerd's model rank GERN?
As at 21 Nov 2026, Geron Corp. ranks 71 out of 100 on Ticker Nerd's systematic factor model — a percentile across roughly 4,300 US stocks, built from its factor families. Its strongest factor family is Value (93 of 100).
Will GERN stock go up?
No one can know that. What the data says: the median 12-month target from 5 analysts is $3.25, and Ticker Nerd's factor model ranks Geron Corp. 71 out of 100 as at 21 Nov 2026. Analyst targets are third-party estimates and frequently wrong; none of this is personal advice.
What is the GERN stock forecast for 2030?
No analyst covering Geron Corp. publishes a 2030 price target — Wall Street targets run 12 to 18 months out. Sites quoting a 2030 price for GERN are extrapolating price history, which says nothing about the business. The furthest attributed numbers are the current analyst targets: $2.5 to $5 over the next 12 months.
How has GERN stock performed over the past year?
Geron Corp. returned -20.8% over the 12 months to 20 Nov 2026, with dividends reinvested. Past performance does not indicate future returns.
What does Geron Corp. do?
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers and related hematologic disorders. Its lead product is RYTELO (imetelstat), a telomerase inhibitor used in the treatment of adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia.
About Geron Corp.
Geron Corporation is a commercial-stage biopharmaceutical company focused on developing and commercializing therapies for blood cancers and related hematologic disorders. Its lead product is RYTELO (imetelstat), a telomerase inhibitor used in the treatment of adult patients with lower-risk myelodysplastic syndromes who have transfusion-dependent anemia. The company’s work centers on oncology programs that target abnormal blood-forming cells, with an emphasis on myeloid malignancies and other disorders of the bone marrow and blood. Geron Corporation serves the specialized hematology-oncology market by advancing targeted treatment options for patients with limited alternatives, supporting use across clinical practice, specialty care settings, and disease-focused treatment centers. Headquartered in Foster City, California, Geron Corporation is positioned as a focused biotechnology company built around telomerase inhibition and commercial therapy development.
CEO Mr. Harout Semerjian · 258 employees · United States · https://www.geron.com